ApoGen Biotechnologies

Recent Finacing

Series A ext

Recent Raise

$4M

ApoGen develops selective small‑molecule inhibitors and companion diagnostics targeting APOBEC cytidine deaminases to prevent APOBEC‑driven cancer mutagenesis and therapy resistance, leveraging University of Minnesota‑licensed technology.

Founded 2014

Washington, United States

1-10

Private

apogenbiotech.com

Highlights

Focus Areas

Biotechnology

Health Care

Pharmaceutical

Recent Investors

Financials

$11M

Total Raised

2

Funding rounds

10

Investors

Team

Upgrade to view the team

See the team members at ApoGen Biotechnologies.